Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acquisition
Biotech
Lilly lands next-gen pain asset in $1B SiteOne acquisition
SiteOne's lead sodium channel inhibitor was well-tolerated and improved patients' pain tolerances in a recent phase 1 trial.
Darren Incorvaia
May 27, 2025 11:30am
Concentra swoops in to purchase struggling Kronos
May 1, 2025 3:07pm
Chimerix had 8 suitors: Why Jazz won out
Mar 21, 2025 5:17pm
Cell therapy biotech axes cancer trial, turns to autoimmune
Mar 19, 2025 5:35pm
Hookipa walks back Poolbeg purchase plan
Feb 20, 2025 1:34pm
Clinical trial org Flourish Research buys Diablo
Feb 19, 2025 6:00pm
